SCShengchong Chen

Shengchong Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shengchong Chen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Guohua Zhen

    Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    6 shared publications
  • Dian Chen

    Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Natural and Biomimetic Drugs Peking University Third Hospital Beijing China

    5 shared publications
  • Chenli Chang

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    4 shared publications
  • Chenli Chang

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications
  • Yuchen Feng

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications
  • Dian Chen

    Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, and

    2 shared publications

Latest Publications

  • Open Access

    Exogenous IL-25 ameliorates airway neutrophilia via suppressing macrophage M1 polarization and the expression of IL-12 and IL-23 in asthma

    by Chenli Chang, Gongqi Chen, Wenliang Wu, Dian Chen, Shengchong Chen, Jiali Gao, Yuchen Feng, Guohua Zhen

    Background: Severe asthma is associated with substantial mortality and has unmet therapeutic need. A subset of severe asthma is characterized by neutrophilic airway inflammation. Classically activated (or M1) macrophages which express IL-12 and IL-23 are associated with airway neutrophilia in asthma. Exogenous IL-25 was reported to suppress intestinal inflammation in animal models of inflammatory bowel diseases via suppressing IL-12 and IL-23 production. We hypothesize that IL-25 ameliorates airway neutrophilia via inhibiting macrophage M1 polarization and the expression of IL-12 and IL-23 in asthma. Methods: In a mouse model of neutrophil-dominant allergic airway inflammation, the effect of mouse recombinant IL-25 on airway inflammation were assessed by H&E staining and bronchoalveolar lavage (BAL) cell counting. The percentage of M1 macrophages in lung tissue and BAL cells were analyzed by flow cytometry. Quantitative PCR and immunostaining were performed to measure the expression of Il12, Il23, and inflammatory cytokines. Mechanistic experiments were performed in primary culture of macrophages from mouse lungs. The expression of IL-12, IL-23 and IL-25 in sputum was analyzed in a cohort of severe asthma and subjects with eosinophilic or non-eosinophilic asthma. Results: Intranasal administration of IL-25 markedly decreased the number of neutrophils in BAL cells in a murine model of neutrophil-dominant allergic airway inflammation. Moreover, exogenous IL-25 decreased the number of M1 macrophages, and reduced the expression of IL-12, IL-23 in the lungs of the mouse model. Exogenous IL-25 also inhibited the expression of inflammatory cytokines IL-1β, IFN-γ, TNF-α and IL-17 A. In vitro, IL-25 suppressed IL-12 and IL-23 expression in lipopolysaccharide (LPS)-stimulated primary culture of mouse pulmonary macrophages. Mechanistically, IL-25 inhibited LPS-induced c-Rel translocation to nucleus via STAT3-dependent signaling. In a cohort of severe asthma, IL-25 protein levels in sputum were significantly lower than control subjects. The transcript levels of IL-12 and IL-23 were increased whereas IL-25 transcripts were decreased in sputum cells from subjects with non-eosinophilic asthma compared to eosinophilic asthma. Conclusions: IL-25 expression is downregulated in subjects with severe or non-eosinophilic asthma. Exogenous IL-25 ameliorates airway neutrophilia, at least in part, via inhibiting macrophage M1 polarization and the expression of IL-12 and IL-23.


  • Cadherin-26 Amplifies Airway Epithelial IL-4 Receptor Signaling in Asthma

    by Yuchen Feng, Shengchong Chen, Luyang Xiong, Chenli Chang, Wenliang Wu, Dian Chen, Jiali Gao, Gongqi Chen, Lingling Yi, Guohua Zhen

    Activation of IL-4R (IL-4 receptor) signaling in airway epithelial cells leads to airway hyperresponsiveness and mucus overproduction in asthma. CDH26 (cadherin-26), a cadherin implicated in the polarization of airway epithelial cells, is upregulated in asthma. However, the role of CDH26 in asthma remains unknown. In this study, we demonstrated that Cdh26 deficiency significantly reduced airway mucus overproduction, airway hyperresponsiveness, and airway eosinophilia in a murine model of allergic airway disease. Interestingly, allergen-induced Il-4Rα upregulation in airway epithelium was markedly reduced in Cdh26 −/− mice. In cultured human bronchial epithelial cells, CDH26 knockdown inhibited IL-13, a ligand for IL-4R; induced IL-4Rα and IL-13Rα1 (IL-13 receptor α1) upregulation; and suppressed downstream Jak1 (Janus kinase 1) and Stat6 (signal transducer and activator of transcription 6) phosphorylation. Moreover, CDH26 knockdown inhibited IL-13–induced MUC5AC and eosinophilic chemokine expression. These results suggest that CDH26 plays a key role in epithelial IL-4R signaling activation and downstream effectors. In contrast, CDH26 overexpression amplified IL-13–activated IL-4R signaling in BEAS-2B cells. In the airway epithelium of patients with asthma, IL-4Rα expression was elevated, and CDH26 was the only cadherin that was upregulated among 11 cadherin family members. CDH26 expression was strongly correlated with epithelial IL-4Rα and MUC5AC expression, sputum eosinophilia, and fractional exhaled nitric oxide in patients with asthma. Taken together, we identified CDH26 as a key regulator of epithelial IL-4R signaling in asthma and a potential therapeutic target for IL-4R–mediated allergic diseases.


  • Open Access

    Epithelial miR-206 targets CD39/extracellular ATP to upregulate airway IL-25 and TSLP in type 2–high asthma

    by Kan Zhang, Yuchen Feng, Yuxia Liang, Wenliang Wu, Chenli Chang, Dian Chen, Shengchong Chen, Jiali Gao, Gongqi Chen, Lingling Yi, et al.

    The epithelial cell–derived cytokines IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) initiate type 2 inflammation in allergic diseases, including asthma. However, the signaling pathway regulating these cytokines expression remains elusive. Since microRNAs are pivotal regulators of gene expression, we profiled microRNA expression in bronchial epithelial brushings from type 2–low and type 2–high asthma patients. miR-206 was the most highly expressed epithelial microRNA in type 2–high asthma relative to type 2–low asthma but was downregulated in both subsets compared with healthy controls. CD39, an ectonucleotidase degrading ATP, was a target of miR-206 and upregulated in asthma. Allergen-induced acute extracellular ATP accumulation led to miR-206 downregulation and CD39 upregulation in human bronchial epithelial cells, forming a feedback loop to eliminate excessive ATP. Airway ATP levels were markedly elevated and strongly correlated with IL-25 and TSLP expression in asthma patients. Intriguingly, airway miR-206 antagonism increased Cd39 expression; reduced ATP accumulation; suppressed IL-25, IL-33, and Tslp expression and group 2 innate lymphoid cell expansion; and alleviated type 2 inflammation in a mouse model of allergic airway inflammation. In contrast, airway miR-206 overexpression had opposite effects. Overall, epithelial miR-206 upregulates airway IL-25 and TSLP expression by targeting the CD39–extracellular ATP axis, which represents a potentially novel therapeutic target in type 2–high asthma.


  • Increased epithelial galectin‐13 expression associates with eosinophilic airway inflammation in asthma

    by Lingling Yi, Shuchen Zhang, Yuchen Feng, Wenliang Wu, Chenli Chang, Dian Chen, Shengchong Chen, Jianping Zhao, Guohua Zhen

    Background: Airway eosinophilic inflammation is a central feature in asthma which is mainly driven by type 2 response. The expression of galectin‐13 was up‐regulated in a parasitic infection model which is also characterized by type 2 immune response. We hypothesized that galectin‐13 may be involved in airway eosinophilic inflammation in asthma.Objective: To unveil the role of galectin‐13 in asthma airway inflammation.Methods: We measured galectin‐13 expressions in bronchial brushings, sputum, and plasma of asthma patients (n = 54) and healthy controls (n = 15), and analysed the correlations between galectin‐13 expression and airway eosinophilia. We used human bronchial epithelial cell line 16HBE to investigate the possible mechanism by which galectin‐13 participates in eosinophilic inflammation.Results: The expression of galectin‐13 was markedly increased in subjects with asthma compared to controls. Epithelial galectin‐13 mRNA levels in asthmatic subjects were strongly correlated with eosinophilic airway inflammation (the percentage of sputum eosinophils, the number of eosinophils in bronchial submucosa and FeNO) and the expression of Th2 signature genes (CLCA1, POSTN and SERPINB2). Inhaled corticosteroid (ICS) treatment reduced plasma galectin‐13 levels, and baseline plasma galectin‐13 levels reflect the response to ICS treatment. In cultured 16HBE cells, knockdown of galectin‐13 suppressed IL‐13‐stimulated MCP‐1 and eotaxin‐1 expression by inhibiting the activation of EGFR and ERK.Conclusions & Clinical Relevance: Galectin‐13 is a novel marker for airway eosinophilia in asthma, and may contribute to allergic airway eosinophilic inflammation by up‐regulating the expression of MCP‐1 and eotaxin‐1. Plasma galectin‐13 levels may be useful for predicting responses to ICS treatment.


  • Open Access

    An epithelial microRNA upregulates airway IL-25 and TSLP expression in type 2-high asthma via targeting CD39-extracellular ATP axis

    by Kan Zhang, Yuchen Feng, Yuxia Liang, Wenliang Wu, Chenli Chang, Dian Chen, Shengchong Chen, Lingling Yi, Guohua Zhen

    The presence of type 2 inflammation is a prominent endotype of asthma. Airway epithelial cell-derived cytokines IL-25, IL-33 and TSLP initiate type 2 inflammation. However, the upstream signaling pathway regulating these cytokines’ expression remains elusive. We identified a small set of epithelial microRNAs differentially expressed between type 2-low and –high asthma patients. MiR-206 was the most highly expressed microRNA in type 2-high asthma relative to type 2-low asthma, but was downregulated in both asthma subsets compared to control subjects. CD39, an ecto-nucleotidase degrading extracellular ATP, was a target of miR-206 and upregulated in asthma. In cultured human bronchial epithelial cells, allergen-induced rapid accumulation of extracellular ATP was responsible for miR-206 downregulation and CD39 upregulation, suggesting a protective mechanism to eliminate excessive ATP. Importantly, BALF ATP levels were increased in asthma patients, and strongly correlated with elevated IL-25 and TSLP expression in type 2-high asthma. Intriguingly, inhibition of airway miR-206 increased Cd39 expression, suppressed airway ATP accumulation and Il-25, Il-33, Tslp expression, and alleviated type 2 inflammation in a mouse model of asthma. In contrast, airway miR-206 overexpression had opposite effects. Taken together, airway epithelial miR-206 upregulates IL-25, TSLP expression via targeting CD39-extracellular ATP axis in type 2-high asthma.


  • Open Access

    Radiographic Findings and other Predictors in Adults with Covid-19

    by Kaiyan Li, Dian Chen, Shengchong Chen, Yuchen Feng, Chenli Chang, Zi Wang, Nan Wang, Guohua Zhen

    As of March 20, 2020, there were 234,073 confirmed cases of coronavirus disease 2019 (Covid-19) and 9,840 deaths worldwide 1 . Older age and elevated d-dimer are reported risk factors for Covid-19 2,3 . However, whether early radiographic change is a predictor of fatality remains unknown. We retrospectively reviewed records of all laboratory-confirmed patients admitted to a quarantine unit at Tongji Hospital, a large regional hospital in Wuhan, China, between January 31 and March 5, 2020. The Tongji Hospital ethics committee approved this study.


  • microRNA‐218‐5p plays a protective role in eosinophilic airway inflammation via targeting δ‐catenin, a novel catenin in asthma

    by Yuxia Liang, Yuchen Feng, Wenliang Wu, Chenli Chang, Dian Chen, Shengchong Chen, Guohua Zhen

    Background: microRNA (miR)‐218‐5p is involved in cigarette smoke‐induced airway inflammation. In our earlier asthma epithelial miRNA profiling data, miR‐218‐5p was the top 2 down‐regulated miRNA. We hypothesize that miR‐218‐5p plays a role in asthma airway inflammation.Objective: To unveil the role of miR‐218‐5p and its target gene in asthma airway inflammation.Methods: We measured miR‐218‐5p expression in bronchial brushings of asthma patients (n = 50) and healthy controls (n = 15), and analysed the correlations between miR‐218‐5p expression and airway eosinophilia. We examined whether CTNND2 was a target of miR‐218‐5p, and the expression of 12 catenin family members in bronchial brushings, in cultured human bronchial epithelial (HBE) cells and BEAS‐2B cells. We explored the role of miR‐218‐5p‐CTNND2 pathway using a murine model of allergic airway inflammation.Results: Epithelial miR‐218‐5p expression was significantly decreased and negatively correlated with eosinophils in induced sputum and bronchial biopsies, and other type 2 biomarkers in asthma patients. We verified that CTNND2 (encoding δ‐catenin) was a target of miR‐218‐5p. Remarkably, CTNND2 was the most significantly up‐regulated catenin compared with the other 11 catenin family members in bronchial brushings of asthma patients, IL‐13‐stimulated HBE and BEAS‐2B cells. Moreover, epithelial CTNND2 expression positively correlated with airway eosinophilia in asthma. Airway mmu‐miR‐218‐5p expression was also decreased, and Ctnnd2 expression was increased in a murine model of allergic airway inflammation. Intriguingly, mmu‐miR‐218‐5p overexpression suppressed airway hyperresponsiveness, eosinophilic airway inflammation and Ctnnd2 up‐regulation in the mouse model. Finally, perturbation of miR‐218‐5p or CTNND2 expression significantly altered chemokine CCL26 expression in the cell cultures and the mouse model.Conclusions and Clinical Relevance: Epithelial miR‐218‐5p plays a protective role in eosinophilic airway inflammation via targeting CTNND2, a novel catenin in asthma, and suppressing chemokine CCL26 expression.